In addition, pemigatinib is currently being evaluated as first line treatment for advanced CCA with FGFR2 rearrangement in comparison to gemcitabine/cisplatin in the FIGHT-302 phase 3 trial (NCT03656536) [11]. Here, FGFR2 is linked to cholangiocarcinoma.